Delayed PSMA imaging to detect aggressive prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This study tests whether a special type of imaging scan (PSMA PET/CT with delayed imaging) can better identify aggressive prostate cancer in men who haven't had a biopsy yet. The goal is to help doctors decide who really needs a biopsy and avoid unnecessary procedures.
Summary written for real people, not researchers, by Clin2.
Who can take part
- PSA blood test result of 4.0 or higher
- Suspected prostate cancer (based on PSA or other signs)
- Willing to have a prostate biopsy (a small tissue sample taken)
- Haven't had any prostate cancer treatment before
- No other cancers diagnosed in the past 2 years
- Able to provide written consent and participate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether a special scan called PSMA PET can help predict how prostate cancer will progress. It is for people who have just been diagnosed and have not started treatment yet.
This study uses a special type of imaging scan (PSMA PET) to track how well prostate cancer treatment is working by comparing scans before and after your planned therapy. The goal is to help doctors better understand which treatments work best for your type of cancer.
This study tests whether a special scan (PSMA PET/MRI) combined with a standard MRI can better detect prostate cancer. It is for men who have not had a biopsy yet and are suspected of having prostate cancer.
This study uses two different PSMA PET/CT tracers to see how well they detect cancer in patients with advanced prostate cancer that has spread or stopped responding to hormone therapy. The goal is to improve imaging for better treatment decisions.
This trial tests if a special scan called PSMA PET can help diagnose prostate cancer in men whose MRI results are not clear. It may help avoid unnecessary biopsies.
This study uses a special imaging test (PSMA PET/CT) to better see if men with low-risk prostate cancer are good candidates for active surveillance (monitoring instead of immediate treatment). It helps doctors decide if watching the cancer closely is safe.
Hear when a new Molecular Imaging trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.